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As biology and business become ever
more tightly entwined, the most
basic of research is finding its way to
venture capitalists. The latest
beneficiaries are the olfactory and
taste receptors being pursued by
Senomyx, Inc. (La Jolla, California).
Forget life-threatening disease and
miraculous cures — these folks are
going to bring you a world of
delectable tastes and fragrant scents. 
“We’ve put together big pharma’s
tools to come up with our discovery
engine for smell and taste,” says
Senomyx CEO Paul Grayson. Grayson
is targeting the consumer products
industry because it spends billions on
research, and yet so far has largely
ignored the potential of genomics and
molecular biology. Grayson’s latest
convert is his new vice-president of
research, Mark Zoller. “I was looking
around for something that was the
next wave of using genomics,” says
Zoller, “and I think this is it.”
Receptors and more receptors
The goal of the hunt was simply to possess
everything the world could offer in the way
of odors.*
Senomyx was born in April 1999
thanks to the recent discovery of two
putative taste receptors by Charles
Zuker (University of California, San
Diego) and Nicholas Ryba (National
Institutes of Health, Bethesda,
Maryland). Zuker teamed up with
Lubert Stryer (Stanford University,
Stanford, California) who he knew
from, amongst other places, the
scientific advisory board of Aurora
Biosciences Corporation (San Diego,
California). They recruited Grayson,
then Aurora’s senior vice-president of
corporate development, as their first
CEO. Stryer took off two years from
Stanford to help found the company
and act as its chief scientific officer.
From the initial idea of taste, the
company quickly started thinking
about the science of smell. The
appeal was the lack of regulation
(“Phase III clinical trials are basically
someone smelling it,” says Grayson)
and the more developed state of the
science.The molecular era of olfaction
research had started in 1991 with the
isolation of olfactory receptor genes
by Linda Buck and Richard Axel
(then both at Columbia University in
New York). At last count there were
~1000 olfactory receptor genes in rats
and mice and over 500 in humans
(including pseudogenes).
The precision of modern biological
research comes to the rescue of
the industry of smell. 
Senomyx has intellectual property
covering not only many of these
olfactory receptors, but also a host of
bitter taste receptors discovered by
Zuker and Ryba earlier this year, and
a method for expressing the receptors.
Receptor expression failed initially
because of a lack of membrane
targeting; the solution was a fusion to
the amino terminus of rhodopsin.
Decoding the matrix
When Baldini assigned him a new scent ...
Grenouille no longer reached for flacons and
powders, but instead simply sat himself down
at the table and wrote the formula straight out. 
The first task for Senomyx is to come
up with an olfactory code: a matrix in
which every smelly chemical can be
expressed as a pattern of activated
olfactory receptors. “The proximal
problem of what odors go with what
receptor I think will be solved in the
next two to four years,” says Larry
Katz (Duke University, Durham,
North Carolina). “Relatively soon
we’ll have a molecular fingerprint of
what an odorant looks like to the
olfactory epithelium.”
But will all those matrices make
any sense? From Buck’s work we
know that each olfactory receptor
recognizes multiple odorants (some
clearly related, some not) and that
each odorant is recognized by multiple
receptors. Everyone involved is
hoping that some sense of order falls
out of this combinatorial code. Based
on the psychophysics of smell and the
psychobabble of perfumers “there are
all these odor categories,” says Katz,
“and I think they must have
correlations with groups of receptors.”
Senomyx will use patterns for
several activities, including screens for
inhibitors of malodors. Perhaps the
most lucrative application will be in
establishing the code for a best-selling
perfume, and then ensuring that the
code is maintained even as the
chemical mix is changed. Unnecessary
components of complex perfume
mixtures could be removed, expensive
or unstable components replaced with
cheaper, more stable chemicals, and
new scent combinations devised to
transmit the same odor signature from
the far less volatile emulsion of a
shampoo. In the land of Calvin Klein
et al., it’s all about brand extension.
The receptor assays are a
replacement human nose, capable of
handling the thousands of novel
chemicals that Senomyx is
generating. “If you could screen
50,000 compounds a day with 1 m l of
fragrance per assay in human subjects
we would be out of business,” says
Grayson. “But you can’t.”
What Grayson cannot yet know is
how exact his receptor patterns will
have to be — and how exact of a
match will have to be maintained —
to preserve the precise scent of his
choice. The work of Katz and Buck
suggests that the number of receptors
activated by any single odorant will be
manageable. But establishing how
sensitive the code is —  to altered
affinities or failure to bind 1 of 10
previously occupied receptors — will
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only come once the code is established
and the system tested. Unfortunately,
as Stryer says, “it’s easy to say in a
sentence, but it’s a vast project to
determine the olfactory response
spectrum. It’s the most complex
combinatorial recognition project.”
Will decoding reveal all, and does
receptor biology equal olfaction?
Complexity in olfaction does, indeed,
arise largely from the multitude of
receptors, and those receptors can be
accessed by Senomyx using
extracellular chemicals. The linkage
from the receptors in the olfactory
epithelium to the olfactory bulb is
then simple — each olfactory sensory
neuron appears to display only a
single receptor, and all the dispersed
neurons that display a given receptor
converge on a single pair of glomeruli
in the olfactory bulb. 
Downstream of the glomeruli
some extra complexity creeps in,
including a temporal code identified
by Gilles Laurent of the California
Institute of Technology in Pasadena.
Cells at this level “don’t work
separately but interact and produce
an emergent output,” says Laurent.
“It’s very difficult to look at any of
that in a reductionist way.” And the
later complexities are necessary, says
Laurent, “if you want to get
something that is as reliable and as
noise-resistant as the brain.”
For Senomyx, however, none of
this may matter. “If you can mimic
an activity pattern at the periphery
you will get the same perception,”
says Stryer. The brain take cares of
the rest.
What no one is promising, at least
so far, is mind control. “The emotional
content, how odors bring back
memories and make one feel, are very
important, but receptors will not code
all of that,” says Stryer. “I’m not in the
position to say that a given receptor
activation will seem pleasant.”
The science of the Snortal
Senomyx has competition, at least in
the cloning of olfactory receptors, in
the form of DigiScents, Inc.
(Oakland, California). DigiScents was
formed by Joel Bellenson and
Dexster Smith after their success
with the sequence-massaging
company DoubleTwist, Inc.
(Oakland, California; formerly Pangea
Systems, Inc.). DigiScents promises
that an odor-producing device called
the iSmell “brings the sense of smell
to your computer.” That’s right, folks,
they are going to puff the smells of
gunpowder, pine trees and burning
tires at you as you surf the Net.
The persuasive power of an odor cannot be
fended off, it enters us like breath into our
lungs, it fills us up, imbues us totally. There
is no remedy for it. 
Distribution of the necessary
software will be easy — it is being
bundled with RealPlayer — but the
hardware (with its cartridge of 128
odorants, combinable in millions of
permutations) presents more of a
challenge. “The focus studies we’ve
done have been very very successful,”
says Bellenson. “The response rate
has been over 90% once people
experience it.” The trick may be to
get people to try it in the first place —
to get them past their memories of
the classic John Waters’ film Polyester,
a scratch-and-sniff extravaganza
presented in “Odorama.”
The iSmell will be available by
Christmas, but in the meantime
DigiScents is busy cloning olfactory
receptor genes (with the help of
CLONTECH Laboratories, Inc. of
Palo Alto, California) and
determining an olfactory code akin to
that being derived by Senomyx.
“Those patterns become a
fingerprint for an odor, which allows
us to reproduce that odor later,” says
Bellenson. “We pull the subjectivity
out of the problem.” The code is the
key to creating your very own “Scent
Tracks™” by visiting a website
called, you guessed it, The Snortal™.
A tasty alternative
For all its interest in olfaction,
Senomyx may get its start in
modifying taste. The simplest of all
its proposed projects involves
blocking the response of bitter taste
receptors to products such as
processed foods, nutraceuticals,
antibiotics and artificial sweeteners.
The number of bitter taste receptors
appears to be manageable (perhaps
20–40), and any given bitter chemical
may target only one receptor. “It’s
more like a classical target,” says
Zoller. In contrast, devising
something new — say a tofu with
meat flavor — involves creating new
volatile and non-volatile components,
and “that’s a really difficult problem.”
Projects for the future include
novel sweeteners (based on proposed
sweet receptors isolated by Zuker
and Ryba), and modifiers of possible
receptors for salt and umami (the
flavor of monosodium glutamate).
Senomyx is interested in doing
further basic biology in these areas,
including expression cloning of any
receptors that may still be out there.
“Since a lot of the work is done by
homology and informatics, there is a
lot that you can miss,” says Zoller.
The motivation
The meaning and goal and purpose of his
life had a higher destiny: nothing less than
to revolutionize the odiferous world.
As a refugee from pharmaceutical
science, Zoller has certainly thought
about the contrast between his old
and new goals. “When I tell non-
scientists what I’m doing everybody
thinks it is unbelievably cool,” he
says. “When I tell scientists they
think, ‘You’re not curing osteoporosis
or cancer’.” 
The new science “is very much
targeted to enhancing the enjoyment
of life,” says Stryer. “It relates to day-
to-day living rather than the
amelioration of suffering.” More
serious applications may come, such
as the modification of plant smells to
repel insect predators. But with the
current fuss over genetically modified
foods “we’re not even going down
that road,” says Grayson. “We’ll
revolutionize one industry at a time.”
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